Cytotoxic plants from the Indian subcontinent: promising reservoir of anticancer agents
7 affiliations
- 1Department of Biochemistry and Molecular Medicine, George Washington University, Washington, D.C., United States
- 2Department of Chemistry, Supaul College of Engineering, Supaul, Bihar, India
- 3Department of Botany, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India
- 4Department of Botany, University of Lucknow, Lucknow, Uttar Pradesh, India
- 5Zebrafish Research Laboratory, Department of Life Sciences, Parul Institute of Applied Sciences, Research and Development Cell, Parul University, Vadodara, Gujarat, India
- 6School of Life Sciences, Swami Ramanand Teerth Marathwada University, Nanded, Maharashtra, India
- 7University Department of Botany, Lalit Narayan Mithila University, Darbhanga, Bihar, India
Abstract
In recent decades, cancer has remained the leading cause of mortality globally. The increasing incidence of cancer and the rise in the mortality rate pose substantial challenges for effective management strategies. Currently, several chemotherapeutic agents, including cisplatin, doxorubicin, and gemcitabine, are routinely used as frontline treatment options for cancer. Although these agents exhibit initial efficacy during the early stages of tumor development, their widespread application in clinical settings is significantly limited by their lack of selectivity, high cost, and toxicity to normal tissues. Phytochemicals have been recognized as promising alternatives to address these limitations. Their remarkable anticancer efficacy is attributed to various distinct mechanisms. Additionally, they are cost-effective and relatively nontoxic, which represent a significant advantage over conventional treatment approaches. To date, only a few phytochemicals, including resveratrol, gingerol, curcumin, and epigallocatechin-3-gallate, have progressed to clinical application. However, the current array of these phytochemicals is inadequate to meet the increasing demand for novel medicines against cancer. Thus, ethnopharmacology has emerged as a promising avenue for discovering and developing novel anticancer drugs. Medicinal plants from the Indian subcontinent are a valuable resource of diverse phytochemicals, which have traditionally been used for treating several health conditions and diseases. However, the evaluation of potential of these phytochemicals as anticancer medicines has largely been limited to preliminary screening. Therefore, this review specifically explores potent anticancer plants native to the Indian subcontinent that are yet to undergo rigorous clinical validation. It includes 60 plants from 44 families and details their therapeutic targets in various malignant cancers. It also discusses the major challenges and potential prospects for their effective application in cancer treatment.
Related
- Selection of promising Iranian Alcea species as phenolic-rich medicinal plants based on micromorphological, phytochemical, and antioxidant traits
- Context-dependent regulation of cytotoxic T lymphocytes by nuclear receptors
- Cytotoxic T-cell lymphoma with muscle involvement and germline variants in inborn error of immunity-related genes: clinical and genetic insights from a case series
- Sustained antigenic engagement programs multidimensional CTL states with distinct cytotoxic capacities
- Diagnostic and Clinical Considerations in Myeloid Neoplasms with del(5q): Distinguishing Myelodysplastic Neoplasm with Low Blasts and del(5q) from Myeloid Neoplasms with del(5q) Post-Cytotoxic Therapy
BibTeX
@article{singh2026cytotoxic,
title = {{Cytotoxic plants from the Indian subcontinent: promising reservoir of anticancer agents}},
author = {Vipendra Kumar Singh and Vikas Kumar Singh and Urmilesh Singh and Aditya A. Singh and Ved Prakash and Rashmi P. Sharma and Ankit Kumar Singh},
journal = {BioTechnologia},
year = {2026},
month = aug,
doi = {10.5114/bta/221149},
url = {https://doi.org/10.5114/bta/221149},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cytotoxic plants from the Indian subcontinent: promising reservoir of anticancer agents
AU - Vipendra Kumar Singh
AU - Vikas Kumar Singh
AU - Urmilesh Singh
AU - Aditya A. Singh
AU - Ved Prakash
AU - Rashmi P. Sharma
AU - Ankit Kumar Singh
PY - 2026
DA - 2026/08/20
JO - BioTechnologia
DO - 10.5114/bta/221149
UR - https://doi.org/10.5114/bta/221149
AB - In recent decades, cancer has remained the leading cause of mortality globally. The increasing incidence of cancer and the rise in the mortality rate pose substantial challenges for effective management strategies. Currently, several chemotherapeutic agents, including cisplatin, doxorubicin, and gemcitabine, are routinely used as frontline treatment options for cancer. Although these agents exhibit initial efficacy during the early stages of tumor development, their widespread application in clinical settings is significantly limited by their lack of selectivity, high cost, and toxicity to normal tissues. Phytochemicals have been recognized as promising alternatives to address these limitations. Their remarkable anticancer efficacy is attributed to various distinct mechanisms. Additionally, they are cost-effective and relatively nontoxic, which represent a significant advantage over conventional treatment approaches. To date, only a few phytochemicals, including resveratrol, gingerol, curcumin, and epigallocatechin-3-gallate, have progressed to clinical application. However, the current array of these phytochemicals is inadequate to meet the increasing demand for novel medicines against cancer. Thus, ethnopharmacology has emerged as a promising avenue for discovering and developing novel anticancer drugs. Medicinal plants from the Indian subcontinent are a valuable resource of diverse phytochemicals, which have traditionally been used for treating several health conditions and diseases. However, the evaluation of potential of these phytochemicals as anticancer medicines has largely been limited to preliminary screening. Therefore, this review specifically explores potent anticancer plants native to the Indian subcontinent that are yet to undergo rigorous clinical validation. It includes 60 plants from 44 families and details their therapeutic targets in various malignant cancers. It also discusses the major challenges and potential prospects for their effective application in cancer treatment.
SN - 0860-7796
SN - 2353-9461
ER -